Core Viewpoint - The company has signed a technology development cooperation agreement with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. for the BIOS-0629 project, which includes research, clinical trials, and registration [1] Group 1 - The company will be responsible for the research and development, clinical trials, and registration of the BIOS-0629 project [1] - Zhejiang Zhongshen will handle R&D transformation, post-market production, sales, and market expansion in the Greater China region [1] - The transaction price for the agreement is set at 300 million RMB, with milestone payments of 300 million RMB to be made upon reaching R&D milestones [1] Group 2 - The company will receive a 10% commission on sales revenue from the product once it is launched in the Greater China region [1]
百诚医药：与浙江众神创新医药科技有限公司签署《技术开发合作协议》